Cited by 2,052Genetic factors in colorectal cancerColorectal Cancer Treatments and StudiesColorectal Cancer Screening and Detection

Molecular Basis of Colorectal Cancer

Open access
Markowitz, Sanford D., Bertagnolli, Monica M.·2009·New England Journal of Medicine

Abstract

This review gives an account of recent advances in our knowledge of the molecular mechanisms in colorectal cancer. Genetic changes in the germ line, combined with somatic mutations, occur in familial syndromes of colorectal cancer, whereas somatic mutations are the outstanding feature of sporadic colorectal cancer. Genetic changes drive the progression from adenoma to carcinoma and probably influence individual susceptibility and response to treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmra0804588

Cites

130 of 130 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • KRAS mutations are usually progression events in colon cancers that follow a driver mutation in the Wnt signaling pathway.

    “In contrast, KRAS mutations are usually progression events in colon cancers that follow a driver mutation in the Wnt signaling pathway [43].”

    From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [43]

  • In colorectal cancer, KRAS mutation is a progression event that occurs after Wnt pathway mutation.

    “In contrast, in colorectal cancer KRAS mutation is a progression event that occurs after the initiation event of mutation in the Wnt pathway (57).”

    From KRAS mutation in pancreatic cancer (2021) · cites this paper as [57]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [2]Kinzler KW Vogelstein B Vogelstein B Kinzler KW Colorectal tumors The genetic basis of human cancer 2002 583 612 McGraw-Hill New York 2nd ed
  2. [3]Libutti SK Saltz LB Tepper JE DeVita VT Jr Lawrence TS Rosenberg SA Colon cancer DeVita, Hellman, and Rosenberg's cancer: principles and practice of oncology 2008 1 1232 84 Lippincott Williams & Wilkins Philadelphia

Cited by

Sorted by citations

Authors
Markowitz, S. D., & Bertagnolli, M. M.
Affiliations
  • Howard Hughes Medical Institute (US)
  • Brigham and Women's Hospital (US)
Venue
New England Journal of Medicine
Published
2009-12-17
Volume
361
Issue
25
Pages
2449-2460
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2095692554
Cited by
2,052
References
130
Citations by year
2026: 34 · 2025: 67 · 2024: 96 · 2023: 244 · 2022: 127 · 2021: 145 · 2020: 111 · 2019: 121 · 2018: 120 · 2017: 112 · 2016: 142 · 2015: 149 · 2014: 144 · 2013: 146 · 2012: 127
FWCI
11.33
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Howard Hughes Medical Institute
  • National Cancer Institute (R01CA127306)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
Keywords
colorectal cancer, molecular mechanisms, somatic mutations, germline mutations, sporadic colorectal cancer, adenoma-carcinoma sequence, cancer susceptibility, treatment response
MeSH terms
DNA Repair, Humans, Mutation, Oncogenes, Biomarkers, Tumor, Colorectal Neoplasms, Signal Transduction, Genes, Tumor Suppressor, Genome, DNA Methylation, Genetic Predisposition to Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review